 <h1>Signifor LAR Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>pasireotide</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about pasireotide. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Signifor LAR.</p><h2>In Summary</h2><p><b>Common side effects of Signifor LAR include:</b> asthenia, cholelithiasis, fatigue, hypoglycemia, increased serum alanine aminotransferase, nausea, and vomiting. <b>Other side effects include:</b> adrenocortical insufficiency, hypotension, and increased serum glucose.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to pasireotide: powder for suspension, solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, pasireotide (the active ingredient contained in Signifor LAR) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking pasireotide:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blurred vision</li>
<li>chills</li>
<li>cold sweat</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>darkening of the skin</li>
<li>decreased urine</li>
<li>depression</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>dry mouth</li>
<li>fainting</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>headache</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>loss of appetite</li>
<li>loss of consciousness</li>
<li>muscle pain or cramps</li>
<li>nausea</li>
<li>nightmares</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>pounding in the ears</li>
<li>rapid weight gain</li>
<li>recurrent fever</li>
<li>seizures</li>
<li>shakiness</li>
<li>skin rash</li>
<li>slow, fast, or irregular heartbeat</li>
<li>slurred speech</li>
<li>stomach pain or fullness</li>
<li>sweating</li>
<li>tingling of the hands or feet</li>
<li>trouble breathing</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Clay-colored stools</li>
<li>constipation</li>
<li>darkened urine</li>
<li>dry skin and hair</li>
<li>feeling cold</li>
<li>fever</li>
<li>hair loss</li>
<li>hoarseness or husky voice</li>
<li>indigestion</li>
<li>itching</li>
<li>loss of appetite</li>
<li>muscle stiffness</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>unpleasant breath odor</li>
<li>vomiting of blood</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of pasireotide may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>cough</li>
<li>difficulty with moving</li>
<li>feeling of constant movement of self or surroundings</li>
<li>general feeling of discomfort or illness</li>
<li>joint pain</li>
<li>lack or loss of strength</li>
<li>pain in the arms or legs</li>
<li>sensation of spinning</li>
<li>shivering</li>
<li>stuffy or runny nose</li>
<li>swollen joints</li>
<li>trouble sleeping</li>
</ul><p>
<!-- end powder for suspension, solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pasireotide: intramuscular powder for injection extended release, subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (10%) </p>
<p><b>Common</b> (1% to 10%): Hypotension (7%), prolonged QT (6%), sinus bradycardia (6%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (12%)</p>
<p><b>Common</b> (1% to 10%): Pruritus (8%), dry skin (6%)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Adrenal insufficiency (6%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (58%), nausea (52%), abdominal pain (24%), upper abdominal pain (10%)</p>
<p><b>Common</b> (1% to 10%): Constipation (7%), vomiting (7%), abdominal distention (6%)<sup>[Ref]</sup></p><h3>General</h3><p><b>Very common</b> (10% or more): Asthenia (11%), peripheral edema (10%), decreased appetite (10%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Elevated PTT (47%), elevated PT (33%)</p>
<p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Cholelithiasis (30%), alanine aminotransferase increased (10%), gamma-glutamyl transferase increased (10%)</p>
<p><b>Common</b> (1% to 10%): Aspartate aminotransferase increased (6%)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site reactions (17%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hyperglycemia (40%), diabetes mellitus (18%), glycosylated hemoglobin increased (11%), hypercholesterolemia (10%)</p>
<p><b>Common</b> (1% to 10%): Hypoglycemia (9%), Type 2 diabetes mellitus (9%), lipase increased (7%), hypokalemia (6%), blood glucose increased (6%), blood amylase increased (2%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia (9%), arthralgia (8%), back pain (6%), pain in extremity (6%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%), fatigue (19%)</p>
<p><b>Common</b> (1% to 10%): Dizziness (9%), anxiety (9%), insomnia (9%), vertigo (6%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (13%)</p>
<p><b>Common</b> (1% to 10%): Influenza (9%)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. "Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p></div>
<div class="more-resources" id="moreResources">
<h2>More about Signifor LAR (pasireotide)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: somatostatin and somatostatin analogs</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Signifor LAR &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Signifor</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Acromegaly</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to pasireotide: intramuscular powder for injection extended release, subcutaneous solution</i></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (10%) </p><p><b>Common</b> (1% to 10%): Hypotension (7%), prolonged QT (6%), sinus bradycardia (6%)<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Alopecia (12%)</p><p><b>Common</b> (1% to 10%): Pruritus (8%), dry skin (6%)<sup>[Ref]</sup></p><h3>Endocrine</h3><p><b>Common</b> (1% to 10%): Adrenal insufficiency (6%)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (58%), nausea (52%), abdominal pain (24%), upper abdominal pain (10%)</p><p><b>Common</b> (1% to 10%): Constipation (7%), vomiting (7%), abdominal distention (6%)<sup>[Ref]</sup></p><h3>General</h3><p><b>Very common</b> (10% or more): Asthenia (11%), peripheral edema (10%), decreased appetite (10%)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Elevated PTT (47%), elevated PT (33%)</p><p><b>Common</b> (1% to 10%): Anemia<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Cholelithiasis (30%), alanine aminotransferase increased (10%), gamma-glutamyl transferase increased (10%)</p><p><b>Common</b> (1% to 10%): Aspartate aminotransferase increased (6%)<sup>[Ref]</sup></p><h3>Local</h3><p><b>Very common</b> (10% or more): Injection site reactions (17%)<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hyperglycemia (40%), diabetes mellitus (18%), glycosylated hemoglobin increased (11%), hypercholesterolemia (10%)</p><p><b>Common</b> (1% to 10%): Hypoglycemia (9%), Type 2 diabetes mellitus (9%), lipase increased (7%), hypokalemia (6%), blood glucose increased (6%), blood amylase increased (2%)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia (9%), arthralgia (8%), back pain (6%), pain in extremity (6%)<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%), fatigue (19%)</p><p><b>Common</b> (1% to 10%): Dizziness (9%), anxiety (9%), insomnia (9%), vertigo (6%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Nasopharyngitis (13%)</p><p><b>Common</b> (1% to 10%): Influenza (9%)<sup>[Ref]</sup></p><p id="ref_1">1. "Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals, East Hanover, NJ. </p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. Cerner Multum,  Inc. "Australian Product Information." O 0</p><h2>More about Signifor LAR (pasireotide)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>Drug class: somatostatin and somatostatin analogs</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Signifor LAR &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Acromegaly</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>